Aurobindo Pharma Limited has established a new wholly owned subsidiary in the Philippines as part of its international expansion strategy. The pharmaceutical company announced the incorporation of Aurobindo Pharma Philippines Inc. on January 23, 2026, through its existing subsidiary structure.

Subsidiary Structure and Ownership

The new Philippine entity has been incorporated as a wholly owned subsidiary of Helix Healthcare B.V., which is based in the Netherlands and serves as a wholly owned subsidiary of Aurobindo Pharma Limited. This creates a step-down subsidiary structure that enables the company to expand its operations in the Southeast Asian market.

Financial Investment and Share Capital

The newly incorporated subsidiary has been established with substantial initial funding to support its operations in the Philippines market. The company has made a complete cash subscription to the share capital structure.

Business Objectives and Market Expansion

The primary objective behind establishing Aurobindo Pharma Philippines Inc. is to expand the company's pharmaceutical products business in the Philippines. This strategic move aligns with the company's core pharmaceutical operations and represents a natural extension of its existing business model into new geographic markets.

The subsidiary will operate in the pharmaceuticals industry, focusing on expanding the reach of Aurobindo Pharma's product portfolio in the Philippine market. As a newly incorporated entity, the company does not have historical turnover data, but it is positioned to leverage the parent company's extensive pharmaceutical expertise and product range.

Regulatory Compliance and Approvals

The incorporation process was completed without requiring any governmental or regulatory approvals, indicating a streamlined establishment process. The transaction has been structured as a related party transaction due to the subsidiary relationship, though promoters and the promoter group of Aurobindo Pharma Limited have no direct interest in this particular transaction.

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency with stakeholders and regulatory authorities. This regulatory filing demonstrates the company's commitment to maintaining proper corporate governance standards in its expansion activities.

Aurobindo Pharma shares declined by 2.02% to trade at ₹1,122.20 during Friday afternoon trading, positioning the pharmaceutical company among the top losers on the Nifty Midcap 150 index. The stock movement occurred amid broader market weakness, with the Sensex down 270.84 points and the Nifty declining 75.00 points at the previous close.

Financial Performance Overview

Aurobindo Pharma's consolidated financial results reveal a mixed performance trajectory across different time periods. The company's annual revenue demonstrated growth momentum, increasing by 9.38% from ₹29,001.00 crores in March 2024 to ₹31,723.00 crores in March 2025.

Quarterly Performance Highlights

The company's quarterly performance showed positive trends across key metrics:

Annual Financial Results

The five-year financial performance presents the following consolidated income statement data:

Balance Sheet Strength

The company's balance sheet reflects steady growth in total assets, which increased from ₹45,071.00 crores in March 2024 to ₹49,784.00 crores in March 2025. Fixed assets grew to ₹19,076.00 crores, while current assets reached ₹27,162.00 crores. The reserves and surplus increased to ₹32,595.00 crores, indicating retained earnings growth.

Cash Flow Analysis

Aurobindo Pharma's cash flow statement showed significant improvement in operating activities, generating ₹3,924.00 crores in March 2025 compared to ₹2,434.00 crores in the previous year. The company achieved a positive net cash flow of ₹2,178.00 crores, reversing the negative ₹1,006.00 crores recorded in March 2024.

Key Financial Metrics and Corporate Actions

The company's financial ratios indicate stable operational performance with a basic EPS of ₹59.81 in March 2025, a debt-to-equity ratio of 0.24, and an interest coverage ratio of 15.76. Aurobindo Pharma announced an interim dividend of ₹4.00 per share on August 4, 2025, demonstrating its commitment to shareholder returns.

The pharmaceutical company has a history of corporate actions, including a 1:1 bonus issue announced on May 28, 2015, and a stock split in February 2011 that reduced the face value from ₹5.00 to ₹1.00.